In a report released today, Louise Chen from Cantor Fitzgerald assigned a Hold rating to Teva Pharma (NYSE: TEVA), with a price target of $10. The company’s shares opened today at $11.66, close to its 52-week low of $10.85.
“No comment on 2018 numbers yet. Teva has got its guidance wrong three times this year already, so the company is not providing any numbers for 2018, until the new CEO has had time to review the business in detail.”
According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of -10.6% and a 37.9% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics Inc, Sucampo Pharmaceuticals, and ANI Pharmaceuticals Inc.
Currently, the analyst consensus on Teva Pharma is Hold and the average price target is $15.21, representing a 30.4% upside.
In a report issued on November 3, Deutsche Bank also downgraded the stock to Hold with a $14 price target.
Based on Teva Pharma’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $5.79 billion and quarterly net profit of $614 million. In comparison, last year the company earned revenue of $5.66 billion and had a net profit of $419 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company, which provides patient-centric healthcare solutions. It operates through two segments: Generic Medicines and Specialty Medicines.